


 **Patient presents at service**



Location of nPEP starter packs in _____ Emergency Department

e.g. XXX hospital Starter Packs are located in standard & high-risk packs in ED Ambulatory Care Pyxis machine (Electronic Med Cupboard)

Table 1. PEP recommendations after NON-OCCUPATIONAL exposure to a KNOWN HIV status source

Type of exposure with known HIV-positive source	Estimated risk of HIV transmission per exposure if source NOT on antiretroviral	PEP recommendation	
		Source not on treatment or on treatment with detectable or <u>UNKNOWN</u> viral load	Source viral load <u>KNOWN</u> to be undetectable
Receptive anal intercourse (RAI) - ejaculation - withdrawal	1/70 1/155	3 drugs	Not recommended*
Shared needles and other injecting equipment	1/125	3 drugs	Not recommended*
Insertive anal intercourse (IAI) (uncircumcised)	1/160	3 drugs	Not recommended*
Insertive anal intercourse (IAI) (circumcised)	1/900	3 drugs	Not recommended*
Receptive vaginal intercourse (RVI)	1/1250	3 drugs	Not recommended*
Insertive vaginal intercourse (IVI)	1/2500	3 drugs	Not recommended*
Receptive or insertive oral intercourse	Not measurable	Not recommended†	Not recommended
Mucous membrane and non-intact skin exposure	< 1/1000	3 drugs	Not recommended

* Provided the source history is reliable, they are compliant with medication, attend regular follow-up and have no intercurrent STI.

† PEP may be recommended for receptive oral intercourse with ejaculation if the exposed person has a breach in their oral mucous membrane.

Table 2. PEP recommendations after NON-OCCUPATIONAL exposure to a source with UNKNOWN HIV status

Type of exposure to source with unknown HIV status	Estimated risk of HIV transmission per exposure	PEP recommendation
Receptive anal intercourse (RAI) - ejaculation - withdrawal	1/700* 1/1550*	2 drugs if source MSM or from high prevalence country (HPC)
Shared needles and other injecting equipment	1/12,500† (1/1250 – 1/415‡ if source MSM)	2 drugs if source MSM or from HPC
Insertive anal intercourse (IAI) (uncircumcised)	1/1600*	2 drugs if source MSM or from HPC
Insertive anal intercourse (IAI) (circumcised)	1/9000*	Consider 2 drugs if source MSM or from HPC, particularly if concurrent STI, trauma or blood
Receptive vaginal intercourse (RVI)	1/1,250,000^	Not recommended Consider 2 drugs if source MSM or from HPC
Insertive vaginal intercourse (IVI)	1/2,500,000^	Not recommended Consider 2 drugs if source from HPC
Receptive or insertive oral intercourse	Not measurable	Not recommended
Mucous membrane and non-intact skin exposure	< 1/10,000* (MSM exposure)	Not recommended
Needlestick injury (NSI) from a discarded needle in community	Not measurable	Not recommended

* Based on estimated seroprevalence 10% (9.6%) in MSM.

† Based on estimated seroprevalence 1.0%.

‡ Based on estimated seroprevalence of 29%.

^ Based on estimated seroprevalence 0.1%.

Courtesy of: ASHM HIV- PEP National Guidelines, page 10, *PEP Recommendations*: Revised August 2016

http://www.ashm.org.au/Documents/PEP_GUIDELINES_August.2016.rev%20logo%2030.pdf